The rapid growth characteristics of the sarcoma appear consistent with the multiple somatic mutations that were detected involving CDNK2A, CDKN2B, and GNAS. The CN loss of CDNK2A and CDKN2B predicts loss of CDKN2A and CDKN2B expression, uncoupling the inhibitory role on CDK4/6 to promote tumor cell proliferation (29, 30). This evidence concerns the gene CDK4 and neoplasm.